Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Alexium International Group Wins Key U.S. Air Force Contract For Repellency Treatments

Alexium International Group (ASX: AJX, AX: AJX, OTC QX: AXXIY) has secured a $200,000 contract with the U.S. Air Force Research Laboratory to demonstrate Cleanshell® CB treatments for chemical and biological protection applications.

This contract follows two other purchase orders by the U.S. Army over the last year, and will further validate Reactive Surface Technology for defense applications.

This contract was awarded to further demonstrate Cleanshell® CB on a range of different fabric types and to develop additional performance capabilities over the coming months.

The work will include testing against a range of "live" chemicals, such as Soman and Mustard nerve agents, on a number of Cleanshell® CB treated fabrics.

New reactive particles produced by the Air Force Research Laboratory, as part of Alexium's Cooperative Research and Development Agreement with the U.S. Air Force, will also be incorporated in the fabrics for testing, including against airborne chemical warfare agents.

Stefan Susta, chief operating officer of Alexium International Group, commented: "Alexium is eager to transition the technology to the next stage for defense applications.

"Whilst the defense sector pathway can include extensive material testing, product testing, certifications and field trials, we see this project as an important catalyst to more rapidly qualify and field our protective treatments - which will position the company for larger procurement opportunities."

Large target market

An estimated 200,000 chemical and biological protection suits are purchased annually by the U.S. military for programs such as JPACE, JC3 and JSLIST.

Over 4.5 million JSLIST suits alone have been sold globally since 1997, representing product sales in excess of $800 million.

Cleanshell® CB repellency treatment

Responding to specific military and first responder needs, Alexium developed the Cleanshell® chemistry to offer a new generation of liquid repellency protection in chemical and biological threat scenarios.

Alexium's Cleanshell® CB repellency treatment is targeted specifically to the treatment of the outershell fabric of CB protection ensembles.

The treatment has been optimised to provide excellent water and oil repellency, but has also shown dramatically increased repellency of chemical warfare agent simulants.

Cleanshell® CB offers days of protection versus minutes for conventional fluorocarbon repellency finishes.

It is an environmentally friendly "PFO and PFOA-free" C6 repellency treatment and has been demonstrated on a number of materials, including ballistic protection fabrics.

Analysis

The securing of this new contract with the U.S. Air Force is an important catalyst to more rapidly qualify and field Alexium's protective treatments, which will position the company for larger procurement opportunities.

This contract follows two other purchase orders by the U.S. Army over the last year, and will further validate Reactive Surface Technology for defense applications.

This contract in the defense sector also follows the recently announced Duro contract in the commercial sector for fire retardant nylon treatments, which further demonstrates the widespread interest being generated in Alexium's RST technology.

The market potential of the company's RST treatments is rapidly growing with the U.S. Air Force Research Laboratory contract positioning Alexium to transition to the next stage for defense applications.

Proactive Investors is a market leader in the investment news space, providing ASX "Small and Mid-cap" company news, research reports, StockTube videos and One2One Investor Forums.